The role of CD133 as a potential BCSCs’ biomarker was firstly described in a study by Wright et al., in which an increase in colony-forming efficiency, proliferative rate, and tumourigenic potential was observed in CD133+ cells derived from BRCA1 murine breast tumours [93]. This evidence concerns the gene PROM1 and breast neoplasm.